

図 11. COPD と喘息の気道過敏性 (文献 11 より引用).

喘息 (asthma) の気道過敏性は気道内径 (% FEV1) が正常でも存在するが, COPD (bronchitis, emphysema) の気道過敏性は気道内径が正常域では消失すると考えられる。

因子である¹¹⁾。一方, 喘息に関しても, 気道内径の初期値と気道過敏性は相関を持つが, 気道内径の初期値が正常であっても気道過敏性亢進は存在する (図 11)¹¹⁾¹²⁾。

次に, 喘息の気道過敏性が図 12 に示した種々の刺激 (例えばブラジキニン吸入¹³⁾や運動・過換気¹⁴⁾に対して認められるのに比べ, COPD 患者の気道過敏性亢進は, 気道平滑筋に直接作用する薬剤 (ヒスタミン, アセチルコリン) に対してのみ認められる点である。これは, 喘息での気道過敏性亢進に, 気道を取り巻く自律神経や炎症細胞等の反応性亢進が関与していることを強く示唆する。

B. 治療

前述した病態の違いから, 喘息と COPD では治




図 12. 直接 (気管支平滑筋を直接刺激する) 気道過敏性と間接 (炎症細胞や神経を介した) 気道過敏性. 間接刺激に対する気道過敏性は喘息のみで認められる。

療法も異なる。喘息に関しては, 多彩な浸潤細胞や構築細胞に広く作用点を持つ吸入ステロイドが第一選択薬として推奨される (図 13)¹⁵⁾。吸入ステロイドのみでコントロール不十分な場合には, 長時間作用型 β_2 刺激薬, テオフィリン, 抗ロイコトリエン薬といった気管支拡張薬が Add-on 薬として用いられる (図 14)。

一方, COPD に関しては, 好中球主体の炎症であり, 吸入ステロイドは基準薬としては使えず, さらに疾患特異的な抗炎症やくも未だ無いことから, 気管支拡張薬が第一選択薬として用いられる (図 15)¹⁶⁾。COPD 患者における気管支拡張薬の反応性は, A. 3 の項で述べたように, 抗コリン薬が β_2 刺激薬に優ることに注意を要する。最近の報告によれば長時間作用型気管支拡張薬投与は COPD 患者の症状の予防及びコントロールに有効である。増悪の頻度や程度も軽減し, 患者の健康状態や運動耐容能を増進し, 患者 QOL をも改善させる。

近年, 少数例ではあるが通常量の吸入ステロイドでコントロールできない難治性喘息が注目されている¹⁷⁾¹⁸⁾。その機序として, ステロイドに対する抵抗性が示唆され¹⁹⁾。COPD との類似性を示すのかもしれない。




図 13. 喘息の慢性気道炎症に関与する炎症細胞群と構築細胞群. ステロイドはこれら細胞群に広く作用点を持つ (文献 15 より引用).




図 14. 安定期の気管支喘息管理の模式図. 吸入ステロイドによる炎症の抑制と Add-on 療法による補完を示す.

管理法	●長期酸素療法 (呼吸不全時) ●外科的治療を考慮										
	●吸入ステロイド薬の考慮 (増悪を繰り返す場合)										
	●リハビリテーション ●長時間作用型気管支拡張薬の定期的使用 (単一多剤)										
	●必要時に応じ短時間作用型の気管支拡張薬を使用										
	●危険因子の回避 ●インフルエンザワクチンの接種										
重症度	<table border="1"> <tr> <th>ステージ</th> <th>I: 軽症</th> <th>II: 中等症</th> <th>III: 重症</th> <th>IV: 最重症</th> </tr> <tr> <td>%FEV_{1.0}</td> <td>80% ≤ %FEV_{1.0}</td> <td>50% ≤ %FEV_{1.0} < 80%</td> <td>30% ≤ %FEV_{1.0} < 50%</td> <td>%FEV_{1.0} < 30% または呼吸不全あるいは右室不全の存在</td> </tr> </table>	ステージ	I: 軽症	II: 中等症	III: 重症	IV: 最重症	%FEV _{1.0}	80% ≤ %FEV _{1.0}	50% ≤ %FEV _{1.0} < 80%	30% ≤ %FEV _{1.0} < 50%	%FEV _{1.0} < 30% または呼吸不全あるいは右室不全の存在
ステージ	I: 軽症	II: 中等症	III: 重症	IV: 最重症							
%FEV _{1.0}	80% ≤ %FEV _{1.0}	50% ≤ %FEV _{1.0} < 80%	30% ≤ %FEV _{1.0} < 50%	%FEV _{1.0} < 30% または呼吸不全あるいは右室不全の存在							

図 15. 重症度に応じた COPD の治療法 (文献 16 より引用).

表 1 COPD と喘息の相違点のまとめ

1. 浸潤炎症細胞	COPD: 好中球, マクロファージ, CD8 陽性リンパ球が主体 喘息: 好酸球, 肥満細胞, CD4 陽性リンパ球が主体
2. メディエーターの産生・代謝様式	COPD: NO の ONOO への変換による呼気含量の低下, SP の産生亢進. 喘息: 呼気 NO 含量の上昇, 上皮傷害による SP の分解能低下.
3. 可逆性気道狭窄に関与するメディエーター	COPD: アセチルコリンが唯一の可逆性コンポーネント 喘息: ロイコトリエン, ヒスタミン等の多彩なメディエーターによる気道狭窄
4. 障害の部位 (首座)	COPD: 気道壁の炎症・線維化と肺胞壁の破壊 喘息: 気道全般にわたる炎症はあるが肺胞壁の破壊は無い
5. 気道過敏性亢進の様式	COPD: 閉塞性障害に二次的に発生した過敏性亢進 喘息: 閉塞性障害が消失しても過敏性は存在する. 間接刺激に対する過敏性もあり
6. 薬物療法	COPD: 気管支拡張薬が第一選択薬 (特異的抗炎症薬は未だ無い) 喘息: 吸入ステロイドを第一選択薬とし, 気管支拡張薬を Add-on する

終りに

以上、気管支喘息、COPDの相違点のいくつかについて述べた。概略を表1に示す。両疾患は明らかに異なるが、どちらも罹患率が高いことから²⁰⁾、合併例も有ることは念頭に置くべきである²¹⁾。つまり、明らかな喘息患者が喫煙によって高齢になるに従いCOPDを併発したり、逆にCOPD患者が何らかの原因で喘息を併発する場合である。治療に反応性の乏しい場合には本稿で述べた炎症や、障害部位の違いからもう一方の疾患の治療も一考すれば治療効果改善につながると思われる。

文 献

- 1) Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma. *Lancet* 2002; 360: 1313-22.
- 2) Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. *Nat Rev Immunol* 2008; 8: 183-92.
- 3) Matsunaga K, Yanagisawa S, Ichikawa T, Ueshima K, Akamatsu K, Hirano T, et al. Airway cytokine expression measured by means of protein array in exhaled breath condensate: Correlation with physiologic properties in asthmatic patients. *J Allergy Clin Immunol* 2006; 118: 84-90.
- 4) Barnes PJ. Mediators of chronic obstructive pulmonary disease. *Pharmacol Rev* 2004; 56: 515-48.
- 5) Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2003; 167: 418-24.
- 6) Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Nakajima N, et al. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. *Am J Respir Crit Care Med* 1995; 151: 613-7.
- 7) Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. *Am J Respir Crit Care Med* 2000; 162: 701-6.
- 8) Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. *Chest* 2002; 122: 47-55.
- 9) Barnes PJ. Small airways in COPD. *N Engl J Med* 2004; 350: 2635-7.
- 10) Hamid Q, Song Y, Kotsimbos TC, Bai TR, Hegele RG, Hogg JC. Inflammation of small airways in asthma. *J Allergy Clin Immunol* 1997; 100: 44-51.
- 11) Cockcroft DW. Airway responsiveness In Asthma. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, eds. Lippincott-Raven Publishers, Philadelphia, 1997. p. 1253-66.
- 12) Ichinose M, Takahashi T, Sugiura H, Endoh N, Miura M, Mashito Y, et al. Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and caliber. *Eur Respir J* 2000; 15: 248-53.
- 13) Ichinose M, Miura M, Yamauchi H, Kageyama N, Tomaki M, Oyake T, et al. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. *Lancet* 1992; 340: 1248-51.
- 14) Ichinose M, Nakajima N, Takahashi T, Yamauchi H, Inoue H, Takishima T. A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. *Am J Respir Crit Care Med* 1996; 153: 936-41.
- 15) Barnes PJ, Pederson S, Busse WW. Efficacy and Safety of Inhaled Corticosteroids: New Developments. *Am J Respir Crit Care Med* 1998; 157: S1-S53.
- 16) 日本呼吸器学会 COPD ガイドライン第2版作成委員会(福地義之助他). COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第2版. メディカルレビュー, 2004.
- 17) The ENFUMOSA study group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. *Eur Respir J* 2003; 22: 470-7.
- 18) Wenzel SE, Busse WW. Severe asthma: lessons from the severe asthma research program. *J Allergy Clin Immunol* 2007; 119: 14-21.
- 19) Sugiura H, Komaki Y, Koarai A, Ichinose M. Nitrate stress in refractory asthma. *J Allergy Clin Immunol* 2008; 121: 355-60.
- 20) Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T, et al. Chronic obstructive pulmonary disease (COPD) in Japan: The Nippon COPD Epidemiology (NICE) Study. *Respirology* 2004; 9: 458-65.
- 21) 赤松啓一郎, 一ノ瀬正和. 慢性閉塞性肺疾患(COPD)の気管支喘息合併症例を見逃さないように. *Medical Practice* 2006; 23: 1078-83.



The Possible Role of Hematopoietic Cell Kinase in the Pathophysiology of COPD*

Satoru Yanagisawa, MD; Hisatoshi Sugiura, MD, PhD;
Tomonori Yokoyama, PhD; Toshiyuki Yamagata, MD, PhD;
Tomohiro Ichikawa, MD; Keiichirou Akamatsu, MD, PhD;
Akira Koarai, MD, PhD; Tsunahiko Hirano, MD, PhD;
Masanori Nakanishi, MD, PhD; Kazuto Matsunaga, MD, PhD;
Yoshiaki Minakata, MD, PhD; and Masakazu Ichinose, MD, PhD

Background: Hematopoietic cell kinase (Hck) is a myeloid cell-specific tyrosine kinase, which is known to induce neutrophil infiltration to the lungs. Although the overexpression of Hck causes emphysema-like histologic changes in mice, its expression and activity in patients with COPD are unclear.

Method: The aim of this study was to clarify the expression and activity of Hck in neutrophils from COPD patients, and to investigate the association between the degree of Hck expression and the lung function parameters in COPD patients. Peripheral blood neutrophils were isolated from 22 patients with COPD and 9 healthy subjects (HSs). The protein levels of Hck and phosphorylated Hck were assessed, and the correlation with various background characteristics was evaluated.

Results: The Hck protein level was significantly higher in neutrophils from COPD patients compared with HSs (COPD patients, 1.094; HSs, 0.801; $p < 0.05$). A significant positive correlation was observed between the protein level of Hck and the surface expression of the integrin molecule CD-11b ($r = 0.540$; $p < 0.01$) or CXC chemokine receptor-1 ($r = 0.432$; $p < 0.05$). In contrast, there was no difference in the phosphorylation of the Hck protein between COPD patients and HSs.

Conclusion: The Hck protein level in peripheral blood neutrophils was increased in COPD patients, suggesting that Hck might have an important role in the neutrophil function and play a key role in the pathophysiology of COPD. (CHEST 2009; 135:94–101)

Key words: airway obstruction; CD-11b; CD-18; COPD; CXC chemokine receptor-1; CXC chemokine receptor-2; hematopoietic cell kinase; peripheral blood neutrophil

Abbreviations: CXCR = CXC chemokine receptor; FITC = fluorescein isothiocyanate; Hck = hematopoietic cell kinase; HRP = horseradish peroxidase; HS = healthy subject; PE = phycoerythrin; p-Hck = phosphorylated-hematopoietic cell kinase

COPD is associated with abnormal inflammatory responses, predominantly in small airways and lung parenchyma.¹ Although a multiplicity of cells and mediators are involved in the pathophysiology of COPD,^{2,3} neutrophils are thought to play a key role in the development and progression of the disease.^{4,5} Indeed, both the actual number of neutrophils and the number of neutrophil chemoattractants were up-regulated in induced sputum or BAL fluid samples from patients with COPD.^{6,7}

The mechanisms responsible for neutrophil transmigration into the lungs involve many steps and

molecules. Among these molecules, Mac-1 (CD-11b/CD-18) and CXC chemokine receptor (CXCR) play a pivotal role in this process. Mac-1 is the most important adhesion molecule for neutrophils.⁴ Similarly, CXCR is a key receptor for interleukin-8.⁸ Many reports^{4,8} have shown that the expressions of both molecules were up-regulated in the airways and lungs of patients with COPD. Recently, we have shown⁹ that the expressions of CD-11b and CXCR-1 were enhanced in peripheral blood neutrophils from patients with COPD compared with healthy subjects. These results suggest that the circulating neu-

trophil phenotype has been altered in patients with COPD and may contribute to the pathogenesis of COPD. However, the intracellular signal transduction pathways causing neutrophils to infiltrate into the inflamed lung have been less well understood. Furthermore, few data have been reported on the phenotype of peripheral blood neutrophils in COPD.

Concerning the leukocyte function, both adhesion and chemoattractant properties are blocked by tyrosine kinase inhibitors,¹⁰ and there is much evidence that Src family tyrosine kinase is a key molecule mediating the integrin-signaling pathway in myeloid cells.¹¹ Hematopoietic cell kinase (Hck) is a non-receptor-mediated tyrosine kinase of the Src family, the expression of which is restricted to hematopoietic cells, predominantly in neutrophils.¹² Although the function of Hck overlaps with that of other Src family tyrosine kinases,¹³ Hck is known to modulate adhesion,¹⁴ granulocytosis,¹⁵⁻¹⁷ and cytokine production¹⁸ in neutrophils. Some reports^{19,20} have suggested an association between pulmonary disease and Hck activity. The activation of Hck has been observed in oxidant-induced lung injury, and the inhibition of Src family protein kinase attenuated the lung injury by reducing the alveolar macrophage activities.¹⁹ It has been also demonstrated that the overexpression of Hck in mice caused an enhancement of adhesion-dependent neutrophil activation in response to inflammatory cytokines and the development of emphysematous lung.²⁰ However, the expression of Hck in neutrophils from patients with COPD is still unknown. Furthermore, the correlation between the degree of Hck expression and the baseline characteristics in patients with COPD, including lung function, age, and smoking status, has not yet been elucidated.

The aim of the present study was to clarify whether the expression and activity of Hck in peripheral blood neutrophils are up-regulated in COPD patients. In addition, we also investigated whether the expression of Hck is linked to the pathophysiology of COPD.

*From the Third Department of Internal Medicine, School of Medicine, Wakayama Medical University, Wakayama, Japan. This work was supported in part by grants-in-aid for scientific research from the Japanese Society for the Promotion of Science (No. 17590801).

The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Manuscript received December 17, 2007; revision accepted July 22, 2008.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/mise/reprints.shtml).

Correspondence to: Masakazu Ichinose, MD, PhD, Professor and Chairman, Third Department of Internal Medicine, Wakayama Medical University, School of Medicine, 811-1 Kimiadera, Wakayama 641-8509, Japan; e-mail: masakazu@wakayama-med.ac.jp

DOI: 10.1378/chest.07-3020

MATERIALS AND METHODS

Subjects

This study was approved by the Ethics Committee of Wakayama Medical University. Informed written consent was obtained from all subjects. Twenty-two patients with mild-to-severe COPD (stage I, 3 patients; stage II, 10 patients; stage III, 7 patients; stage IV, 2 patients) and 9 healthy subjects (HSs) with normal lung function were recruited from the outpatient clinic of our institution. Because the prevalence of COPD was appreciably higher in men than in women, all subjects enrolled in this study were men. COPD was defined and categorized according to the Global Initiative for Chronic Obstructive Lung Disease guidelines.¹ All COPD patients were considered to be clinically stable because none of them had required a change in their regular therapy during the 4 months preceding the test, nor had they been treated with inhaled or oral corticosteroids. Patients with bronchial asthma, pneumonia, or lung cancer were excluded from the study. The smoking history of each subject was represented by the mean number of pack-years of cigarette consumption by ex-smokers and current smokers. It was calculated as follows:

$$\text{pack-year} = (\text{number of cigarettes smoked per day}/20 [\text{a pack}]) \\ \times \text{duration of smoking (in years)}$$

All patients refrained from smoking for 12 h before the blood sampling. After the blood sampling, the subjects performed spirometry.

Lung Function Testing

Lung function was evaluated with a dry rolling-seal spirometer (System 7; Minato Medical Science; Osaka, Japan). Each measurement was performed 15 min after the inhalation of 400 μg of salbutamol via a metered-dose inhaler.

Isolation of Peripheral Blood Neutrophils

Human peripheral blood neutrophils were isolated from whole blood by a density gradient technique using a resolving medium (Mono-Poly resolving medium; Dainippon Pharmaceutical Co Ltd Laboratory Products; Osaka, Japan), as previously reported.⁹ Briefly, whole blood was collected by vein puncture into tubes containing ethylenediaminetetraacetic acid anticoagulant. Then, the blood samples were gently mounted onto the same volume of Mono-Poly resolving medium without mixing. The samples were then centrifuged at 400g for 20 min at room temperature. The blood was separated into four layers from the top, as follows: plasma; lymphocytes/mononuclear cells; neutrophils; and RBCs. The neutrophil fraction was collected by Pasteur pipettes without aspirating the other layers. This procedure yields neutrophils with > 95% purity and viability as determined by trypan blue staining. After washing in phosphate-buffered saline solution and counting the cell number, neutrophils were suspended in phosphate-buffered saline solution at a concentration of 1×10^7 cells/mL. Then the expression of each surface molecule was measured by flow cytometer, and the Hck protein level was analyzed by immunoprecipitation and Western blotting.

Flow Cytometry Analysis

The surface expressions of Mac-1 (CD-11b/CD-18), CXCR-1, and CXCR-2 in HSs and COPD patients were measured (FACS Calibur flow cytometer; Becton Dickinson; San Jose, CA). Briefly, 1×10^6 neutrophils were incubated with 20 μL of each

antibody solution for 20 min at 4°C. After washing, the samples were fixed by 500 μ L of a 1% paraformaldehyde solution, then the binding of each antibody was detected by flow cytometer. The specific binding of each antibody was expressed as relative fluorescence shown by the ratio of the mean fluorescence intensity values for CD-11b, CD-18, CXCR-1, or CXCR-2 to that of the isotype control.²¹

Immunoprecipitation and Western Blotting

A total of 1×10^6 neutrophils were lysed using 200 μ L of lysate buffer (500 mmol/L Tris-HCl, 143 mmol/L KCl, 4 mmol/L ethylenediaminetetraacetic acid, 1% Nonidet P-40 lysis buffer, and complete protease/phosphatase inhibitors) for 30 min on ice. Cell-free lysates were incubated with 10 μ L of anti-Hck antibodies for 12 h at 4°C. Then, 10 μ L of protein G-sepharose was added, and the mixture was incubated for an additional 1 h. After the immune complexes had been washed three times, all samples were resuspended in 25 μ L of lysate buffer, mixed with the same volume of $2 \times$ sodium dodecyl sulphate-polyacrylamide gel electrophoresis sample buffer, and then boiled at 100°C for 5 min. The same volume of each sample was applied, and proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (using a 12.5% gradient polyacrylamide gel) [XV Pantera system; DRC Co, Ltd; Tokyo, Japan]. Following electrophoresis, the proteins were transferred to nitrocellulose membranes.

For the assessment of Hck or phosphorylated Hck (p-Hck) protein levels, membranes were blocked and incubated with anti-Hck antibodies (1:5,000 dilution) or antiphosphotyrosine (1:10,000 dilution). Then they were incubated with horseradish peroxidase (HRP)-conjugated antirabbit or antimouse secondary antibody (1:10,000 dilution) and were developed by a detection system (ECL-Plus; Amersham Biosciences; Buckinghamshire, UK). Each protein level was represented as the relative ratio to the expression level of one COPD patient, whose FEV₁ was 50% of the predicted volume.

Reagents

A medium was used for separating polymorphonuclear leukocytes from whole blood cells (Mono-Poly resolving medium; Dainippon Pharmaceutical Co Ltd Laboratory Products). Fluorescein isothiocyanate (FITC)-conjugated antihuman CD-18, FITC-conjugated antihuman CXCR-2 antibody, phycoerythrin (PE)-conjugated antihuman CD-11b, PE-conjugated antihuman CXCR-1 antibody, and FITC- or PE-conjugated Ig G1 isotype control were used (BD Biosciences; San Jose, CA). Other commercially available reagents and antibodies were obtained, as follows: Protein-G sepharose was from Amersham Biosciences; antiphosphotyrosine antibody was from Upstate (Lake Placid, NY); antihuman Hck antibody was from Santa Cruz Biotechnology, Inc (San Diego, CA); and HRP-conjugated antirabbit IgG antibody and HRP-conjugated antimouse IgG antibody were purchased from Rockland (Gilbertsville, PA).

Statistical Analysis

The data were expressed as the mean \pm SD. We checked the distribution of values using the Kolmogorov-Smirnov test. The statistical analysis of the expression of integrin Mac-1 molecule (CD-11b/CD-18), chemokine receptors (CXCR-1/CXCR-2), Hck protein level, and p-Hck level were performed using analysis of variance and the Mann-Whitney *U* test. The analysis of correlations between each factor was performed using the Spearman correlation coefficient rank test. A value of $p < 0.05$ was considered to be significant.

RESULTS

The subjects' characteristics are shown in Table 1. FEV₁, FEV₁/FVC ratio, and FEV₁ percent predicted were significantly lower in COPD patients than in HSs. There was no significant difference in the other pulmonary function parameters. The patients with COPD had a significantly longer smoking history than HSs.

The Hck protein in peripheral blood neutrophils was detected by Western blotting as two protein bands, p59 and p60 (Fig 1, *left, A*). The total Hck protein level was significantly increased in the COPD patients compared with the HSs (COPD patients, 1.094; HSs, 0.801; $p < 0.05$) [Fig 1, *right, B*]. There was a significant negative correlation between the protein level of Hck and the severity of air-flow limitation shown by FEV₁ percent predicted ($r = -0.509$; $p < 0.01$) [Fig 2, *top left, A*]. There was no significant correlation between the Hck protein level and the parameters of lung volume such as FVC percent predicted and inspiratory capacity percent predicted, as shown in Figure 2, *top right, B*, and *bottom, C*.

We next evaluated the relationship between the baseline characteristics and Hck protein levels. Although the COPD patients in the present study had a longer smoking history, there was no apparent correlation between the levels of Hck and smoking history as represented by the number of pack-years of smoking ($r = 0.246$; $p = 0.182$). Furthermore, neither subjects' age nor body mass index showed any relationship with Hck protein levels.

Because CXCRs are involved in the function of neutrophils and are associated with Hck activation, we next studied whether the surface expression of these molecules had some relationship with the Hck protein level. As shown in Figure 3, the Hck protein level was significantly correlated with the expression of CD-11b ($r = 0.540$; $p < 0.01$) and CXCR-1 ($r = 0.432$; $p < 0.05$), but not with that of CD-18 and CXCR-2.

Considering that Hck exerts its function in an active form, there remains a possibility that the protein level of Hck might not necessarily represent the intracellular signaling status. Therefore, we next evaluated the phosphorylation of Hck protein, which is the active form of Hck. The p-Hck protein in peripheral blood neutrophils was detected by Western blotting, and the degree of phosphorylation was assessed by dividing the p-Hck protein by the total Hck protein level. The HSs and COPD patients showed almost the same levels of p-Hck (HSs, 1.369; COPD patients, 1.475; $p = 0.747$) or adjusted p-Hck (HSs, 1.689; COPD patients, 1.394; $p = 0.053$). Neither the p-Hck nor the adjusted p-Hck level showed

Table 1—Baseline Characteristics of Study Subjects*

Characteristics	Healthy Subjects (n = 9)	COPD Patients (n = 22)	p Value
Age, yr	61.3 ± 12.5	70.1 ± 7.8	NS
Gender, No.			
Male	9	22	
Female	0	0	
Smoking status, No.			
Nonsmoker	1	0	
Ex-smoker	5	19	
Current smoker	3	3	
Smoking history, pack-yr	42.9 ± 24.7	77.0 ± 22.3	< 0.01
VC			NS
L	3.72 ± 0.67	3.37 ± 0.73	
% predicted	106.4 ± 15.2	103.7 ± 18.2	NS
FVC			NS
L	3.47 ± 0.66	3.24 ± 0.68	
% predicted	98.6 ± 16.7	94.7 ± 15.6	NS
IC			NS
L	2.27 ± 0.68	2.21 ± 0.46	
% predicted	95.6 ± 23.8	102.3 ± 18.5	NS
FEV ₁			< 0.001
L	2.79 ± 0.55	1.52 ± 0.58	
% predicted	104.5 ± 17.2	56.5 ± 19.4	< 0.001
FEV ₁ /FVC ratio, % predicted	80.7 ± 7.55	46.1 ± 13.4	< 0.001

*Values are given as the mean ± SD, unless otherwise indicated. VC = vital capacity; IC = inspiratory capacity; NS = not significant.

correlations with the background characteristics, except for the expression of the adjusted p-Hck, which correlated with the amount of smoking ($r = -0.432$; $p < 0.05$) [Table 2]. In addition, neither the level of p-Hck nor the adjusted level of p-Hck protein was correlated with the pulmonary function parameters or with the expression of surface molecules.

DISCUSSION

In the present study, we have shown for the first time that the expression of Hck protein in peripheral

blood neutrophils was increased in the patients with COPD. In addition, this increase in Hck protein was significantly correlated with the severity of air-flow limitation and with neutrophil surface molecules such as CD-11b and CXCR-1. These results suggest that Hck might play an important role in the pathophysiology of COPD.

Src family tyrosine kinases are well-known signaling molecules.¹¹ Although they were originally investigated in terms of cell proliferation¹¹ and tumor genesis,²² Src family tyrosine kinases are sensitive to




FIGURE 1. Expression of Hck protein in peripheral blood neutrophils. A representative photograph of Western blotting of Hck (left, A) and the Hck protein level in neutrophils from healthy subjects and COPD patients (right, B). The values indicate mean value of Hck protein levels.




FIGURE 2. Correlation between the Hck protein level and pulmonary function. Correlation between the Hck protein level and FEV₁ percent predicted (top left, A), FVC percent predicted (%FVC) [top right, B] and inspiratory capacity percent predicted (%IC) [bottom, C].

oxidative stress such as H₂O₂²³ or ultraviolet irradiation,²⁴ and their association with tissue remodeling after ischemic or oxidative damage has been described.²⁵ Hck is one of the Src family tyrosine kinases, predominantly expressed in neutrophils,¹² and it was relevant to various neutrophil functions such as activation,¹⁰ adhesion,¹⁴ and degranulation.^{15–18} More recently, the involvement of Hck in inflammatory lung diseases has been demonstrated.²⁰ In transgenic mice with constitutively activated Hck protein, neutrophils accumulated in the lungs and caused emphysematous changes.²⁰ These results suggested the possibility of Hck having some role in the pathophysiology of COPD.

The present study showed that the Hck protein level in peripheral blood neutrophils was significantly increased in COPD patients. In a previous report²⁶ evaluating the effects of polymorphisms on Hck gene expression, Hck protein from polymorphonuclear leukocytes was up-regulated in COPD patients. According to this report, the 8657 L/S polymorphism in intron-1 of the Hck gene was consistently associated with the increased expression of Hck protein, and COPD patients tended to have 8657 L/S subtypes.

These results are consistent with our present data. However, in the present study, we also showed a negative correlation between the increase in the Hck protein level and the severity of air-flow limitation. Thus, it is considered that the increase in the level of Hck protein might facilitate the activation of neutrophils and therefore be involved in the progression of COPD.

The Hck protein levels did not correlate with the subjects' background characteristics. Because the prevalence of COPD is higher in men than in women, it happened that only male subjects were enrolled in this study. According to a previous report²⁶ that examined genetic differences regarding Hck polymorphisms, the factor of gender affected neither the polymorphism frequency nor the protein level of Hck. Therefore, we expected that the same results would have been obtained if female subjects had been enrolled in the present study.

Recently, we reported⁹ that the surface expressions of integrin molecule CD-11b and CXCR-1 were up-regulated in peripheral blood neutrophils and were significantly correlated with the severity of the air-flow limitation. These results suggest that




FIGURE 3. Correlation between the Hck protein level and surface molecule expression. Correlation between the Hck protein level and the expression of CD-11b (top left, A), CD-18 (top right, B), CXCR-1 (bottom left, C), and CXCR-2 (bottom right, D). Each surface molecule was analyzed by flow cytometry and is shown as the relative mean fluorescence intensity (MFI) ratio to the isotype control.

neutrophils are already primed in the systemic circulation, modifying the COPD pathogenesis by augmenting neutrophil infiltration in the airways. Because Hck protein modulates the trafficking of intracellular granules following Mac-1 or CXCR-1 stimulation,^{15,17} we next evaluated the relationship between the amount of Hck protein and the degree of Mac-1 and CXCR expression in neutrophils. As shown in Figure 3, there was a significant positive correlation between the Hck protein levels and CD-11b and

CXCR-1 expression. These findings suggest interesting possibilities. First, because Hck has been reported to promote Mac-1- and CXCR-1-mediated granulocytosis in neutrophils,^{15,17,18} increased Hck levels may further enhance this reaction. Previous studies^{4,27} have shown that degranulation and protease activities are enhanced in neutrophils from patients with COPD. Although we did not investigate the degree of granule release from neutrophils in this study, a previous report by Zhang et al²⁶ has shown that enhanced Hck expression was correlated with the release of myeloperoxidase and a decline in lung function. Therefore, Hck might be involved in the pathogenesis of COPD through modification of the degranulation from neutrophils. Second, Hck may modulate Mac-1 and CXCR expression in neutrophils. To our knowledge, there is no report concerning this. Further study is needed to clarify these issues.

It has been reported that the phosphorylation of Tyr⁴¹⁰ in the Hck protein is needed for its activation.¹⁷ Therefore, we evaluated whether the degree

Table 2—Correlation Coefficients Between p-Hck or Adjusted p-Hck Level and Characteristics of Study Subjects*

Variables	p-Hck	Adjusted p-Hck
Age	-0.055	-0.259
Pack-years of smoking	-0.242	-0.432†
BMI	-0.241	0.019

*Values are given as Spearman correlation coefficients. BMI = body mass index.

† $p < 0.05$.

of phosphorylation of the Hck protein was associated with the pulmonary function or surface molecule expression of neutrophils. Neither the pulmonary function nor the neutrophil cell surface molecules had any correlations with p-Hck levels. In addition, even when the p-Hck level was adjusted by the total Hck protein level, there was no significant correlation. There are some possible explanations for these results. First, the amount of Hck protein that is biologically active might be more important in the pathophysiology of COPD. According to genetic research²⁶ on the Hck gene, polymorphisms of Hck did not occur in the catalytic domain (phosphorylation site), but most frequently in the noncoding region, which seemed to affect the transcriptional process and messenger RNA stability of the Hck gene product. In addition, the frequency of polymorphisms in the noncoding region was well correlated with the activation of neutrophils in terms of myeloperoxidase release, suggesting that the amount of Hck protein, not the degree of Hck phosphorylation, might be more important. Several reports²⁸ regarding human solid tumors have also shown that the absolute protein level of Src-kinase was more important than the phosphorylated protein level in terms of its biological activities.

Second, we might not have detected the precise phosphorylation sites of Hck protein. Hck has two phosphorylation sites, Tyr⁴¹⁰ and Tyr⁵⁰¹. In the case of activation, Tyr⁴¹⁰ is phosphorylated and Tyr⁵⁰¹ should be dephosphorylated. Because we used a nonspecific anti-phosphotyrosine antibody that cannot distinguish Tyr⁴¹⁰ from Tyr⁵⁰¹, we could not detect the true phosphorylated site. Therefore, p-Hck might not indicate the active form of Hck. This may also be the reason why the adjusted p-Hck level was negatively correlated with the number of pack-years of smoking. If p-Hck represented the inactivated form of Hck, the negative correlation would indicate a reverse correlation. In other words, the active form of Hck increased as the number of pack-years of the consumption of cigarettes increased. Further evaluation with a specific anti-phosphotyrosine (Tyr⁴¹⁰) antibody will be necessary to clarify the correlation between the activated Hck levels and the background characteristics. Third, it might be due to the steady state of the neutrophils used in the present study. Hck is known to be activated mainly through two pathways. One is a receptor-mediated mechanism stimulated by various cytokines such as interleukin-8,¹⁷ and the other is an integrin-mediated mechanism.¹⁵ Because our COPD subjects were in a stable condition, Hck might not be fully activated. But increased Hck protein levels might have a potential reactivity in the case of external stimulation during acute exacerbations. That is, the more Hck protein

there is, the more easily it can be phosphorylated; subsequently, a much stronger activation of neutrophils would occur, which might cause an enhancement of airway inflammation and the progression of COPD.

In conclusion, we showed the increased expression of Hck protein in peripheral blood neutrophils in COPD patients, which was significantly correlated with the severity of the air-flow limitation. Considering that the Hck protein level was also relevant to the expression of the neutrophil surface molecules such as CD-11b and CXCR-1, it seemed that Hck might have an important role in the neutrophil function and might play a key role in the COPD pathophysiology. Further clarification of the precise mechanisms of Hck may improve the understanding of the pathogenesis of COPD and provide clues for new therapeutic approaches.

ACKNOWLEDGMENT: The authors thank Mr. Brent Bell for reading the manuscript.

REFERENCES

- 1 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2007. Available at: <http://www.goldcopd.org/>. Accessed October 3, 2008
- 2 Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur Respir J* 2003; 22:672–688
- 3 Barnes PJ. Mediators of chronic obstructive pulmonary disease. *Pharmacol Rev* 2004; 56:515–548
- 4 Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. *Thorax* 2001; 56:432–437
- 5 Stockley RA. Neutrophils and the pathogenesis of COPD. *Chest* 2002; 121(suppl):151S–155S
- 6 Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 1993; 92:537–548
- 7 Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor- α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. *Am J Respir Crit Care Med* 1996; 153:530–534
- 8 Qui Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2003; 168:968–975
- 9 Yamagata T, Sugiura H, Yokoyama T, et al. Overexpression of CD-11b and CXCR-1 on circulating neutrophils: its possible role in chronic obstructive pulmonary disease. *Chest* 2007; 132:890–899
- 10 Berton G. Tyrosine kinases in neutrophils. *Curr Opin Hematol* 1999; 6:51–58
- 11 Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. *Annu Rev Cell Dev Biol* 1997; 13:513–609
- 12 Ziegler SF, Marth JD, Lewis DB, et al. Novel protein-tyrosine kinase gene (Hck) preferentially expressed in cells of hematopoietic origin. *Mol Cell Biol* 1987; 7:2276–2285
- 13 Lowell CA, Soriano P, Varmus HE. Functional overlap in the

- src gene family: inactivation of Hck and fgr impairs natural immunity. *Genes Dev* 1994; 8:387-398
- 14 Giagulli C, Ottoboni L, Cavegion E, et al. The Src family kinases Hck and Fgr are dispensable for inside-out, chemoattractant-induced signaling regulating β 2 integrin affinity and valency in neutrophils, but are required for β 2 integrin-mediated outside-in signaling involved in sustained adhesion. *J Immunol* 2006; 177:604-611
 - 15 Mocsai A, Ligeti E, Lowell CA, et al. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. *J Immunol* 1999; 162:1120-1126
 - 16 Mocsai A, Jakus Z, Vantus T, et al. Kinase pathways in chemoattractant-induced degranulation of neutrophils: the role of p38 mitogen-activated protein kinase activated by Src family kinases. *J Immunol* 2000; 164:4321-4331
 - 17 Barlic J, Andrews JD, Kelvin AA, et al. Regulation of tyrosine kinase activation and granule release through β -arrestin by CXCR1. *Nat Immunol* 2000; 1:227-233
 - 18 Mohn H, Le Cabec V, Fischer S, et al. The src-family protein-tyrosine kinase p59Hck is located on the secretory granules in human neutrophils and translocates towards the phagosome during cell activation. *Biochem J* 1995; 309:657-665
 - 19 Khadaroo RG, He R, Parodo J, et al. The role of the Src family of tyrosine kinases after oxidant-induced lung injury *in vivo*. *Surgery* 2004; 136:483-488
 - 20 Ernst M, Inglese M, Scholz GM, et al. Constitutive activation of the SRC family kinase Hck results in spontaneous pulmonary inflammation and an enhanced innate immune response. *J Exp Med* 2002; 196:589-604
 - 21 Traves SL, Smith SJ, Barnes PJ, et al. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR-2. *J Leukoc Biol* 2004; 76:441-450
 - 22 Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. *Eur J Cancer* 2003; 39:1447-1455
 - 23 Devary Y, Gottlieb RA, Smeal T, et al. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. *Cell* 1992; 71:1081-1091
 - 24 Aikawa R, Komuro I, Yamazaki T, et al. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. *J Clin Invest* 1997; 100:1813-1821
 - 25 Takeishi Y, Huang Q, Wang T, et al. Src family kinase and adenosine differentially regulate multiple MAP kinases in ischemic myocardium: modulation of MAP kinases activation by ischemic preconditioning. *J Mol Cell Cardiol* 2001; 33: 1989-2005
 - 26 Zhang X, Mahmudi-Azer S, Connett JE, et al. Association of Hck genetic polymorphisms with gene expression and COPD. *Hum Genet* 2007; 120:681-690
 - 27 Rodriguez JR, Seaks JE, Rain A, et al. Neutrophil lysosomal elastase activity in normal subjects and in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1979; 119:409-417
 - 28 Borge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. *J Biol Chem* 2000; 275:41439-41446



Contents lists available at ScienceDirect

Respiratory Physiology & Neurobiology

journal homepage: www.elsevier.com/locate/resphysiol



The regulation of amiloride-sensitive epithelial sodium channels by tumor necrosis factor-alpha in injured lungs and alveolar type II cells

Toshiyuki Yamagata^{a,*}, Yuko Yamagata^a, Takeshi Nishimoto^a, Tsunahiko Hirano^a, Masanori Nakanishi^a, Yoshiaki Minakata^a, Masakazu Ichinose^a, André Dagenais^b, Yves Berthiaume^b

^a Third Department of Internal Medicine, Wakayama Medical University, School of Medicine, 1336-99, Musota, Wakayama 641-8509, Japan

^b Centre de Recherche, Centre Hospitalier de l'Université de Montréal-Hôtel-Dieu, and Département de Médecine, Université de Montréal, Montréal, Québec, Canada H2W 1T7

ARTICLE INFO

Article history:

Received 29 May 2008

Received in revised form

21 November 2008

Accepted 12 December 2008

Keywords:

Alveolar liquid clearance

Sodium transport

Epithelial sodium channel

Phorbol ester

Tumor necrosis factor-alpha

ABSTRACT

Alveolar liquid clearance, which mainly depends on sodium transport in alveolar epithelial cells, is an important mechanism by which excess water in the alveoli is reabsorbed during the resolution of pulmonary edema. In this study, we examined the regulation of epithelial sodium channel (ENaC), the main contributor to sodium transport, during acute lung injury and the direct impact of tumor necrosis factor-alpha (TNF- α), one of the important cytokines in acute lung injury, on the ENaC regulation. During the development of pulmonary edema, the increases in the number of neutrophils and the levels of TNF- α in blood and bronchoalveolar lavage were seen. In parallel, the mRNA expression of the α -, β - and γ -ENaC subunits in the whole lung tissue was inhibited to 72.0, 47.8 and 53.9%, respectively. The direct exposure of rat alveolar type II cells to TNF- α inhibited the mRNA expression of α - and γ -ENaC to 64.0 and 78.0%, but not that of the β -ENaC. TNF- α also inhibited the ENaC function as indicated by the reduction of amiloride-sensitive current (control 4.4, TNF- α 1.9 μ A/cm²). These data suggest that TNF- α may affect the pathophysiology of acute lung injury and pulmonary edema through the inhibition of alveolar liquid clearance and sodium transport.

© 2008 Elsevier B.V. All rights reserved.

1. Introduction

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is characterized by an acute inflammatory response due to the damage of the alveolar epithelium or vascular endothelium by various types of stimulation and by the subsequent increase in vascular permeability (Bernard et al., 1994). One of the pathological features is non-cardiogenic pulmonary edema caused by flooding of excess fluid into the alveoli (Ware and Matthay, 2000). In the development of ALI/ARDS, various inflammatory cells and mediators produced by these cells are involved. Among them, a pro-inflammatory cytokine, tumor necrosis factor-alpha (TNF- α), is one of the important cytokines that play a role in the development of ALI/ARDS and pulmonary edema. Indeed, it has been demonstrated that there is an elevation of the TNF- α level in the bronchoalveolar lavage (BAL) from patients with ALI/ARDS (Suter et al., 1992). In addition, it has been also shown that the administration of TNF- α causes the development of respiratory failure due to pulmonary edema (Tracey and Cerami, 1993).

Alveolar liquid clearance is an important mechanism by which excess water in the alveoli is reabsorbed during the resolution of

pulmonary edema. It has been previously reported that the majority of patients with acute lung injury and pulmonary edema show an impairment of alveolar liquid clearance, and that the mortality in these patients is higher than that in those with normal clearance (Matthay and Wiener-Kronish, 1990; Ware and Matthay, 2001). Therefore, to clarify the affecting factors for the regulation of alveolar liquid clearance is important to elucidate the pathophysiology and the therapeutic strategy of ALI/ARDS.

The mechanism of alveolar liquid clearance is operated by active sodium transport across the alveolar epithelium providing a vectorial osmotic driving force into alveoli (O'Brodoovich, 1995; Matthay et al., 1996). This active sodium transport is mainly dependent on the presence of amiloride-sensitive epithelial sodium channel (ENaC) and Na⁺-K⁺-ATPase located on the apical and basolateral surfaces in alveolar type II cells, respectively (Matthay et al., 1996; Berthiaume, 1998). Although there are several other sodium channels and sodium cotransporters expressed in alveolar epithelial cells, the expression and the function of ENaC in particular is thought to be important for active sodium transport as a rate-limiting step in sodium reabsorption from the apical surface (Rossier et al., 1994; Matalon and O'Brodoovich, 1999). Indeed, the importance of ENaC has been demonstrated in a mouse model. When α -subunit of ENaC (α -ENaC) is deleted by gene targeting, these knockout mice die within 40 h after birth because of the development of respiratory distress due to their

* Corresponding author. Tel.: +81 73 462 7584; fax: +81 73 462 7584.
E-mail address: yamagata@jtw.zaq.ne.jp (T. Yamagata).

inability to remove excess liquid in the alveoli (Hummler et al., 1996).

There have been several reports concerning the regulation of ENaC expression and function. For example, β -agonist terbutaline enhances the expression of ENaC through the activation of cyclic adenosine monophosphate (Minakata et al., 1998; Dagenais et al., 2001). Glucocorticoid is also known to enhance ENaC expression and function, demonstrated by an increase in amiloride-sensitive current (Champigny et al., 1994; Tchepichev et al., 1995; Dagenais et al., 2001). On the other hand, the activation of protein kinase c inhibits the expression and function of ENaC (Yamagata et al., 2002, 2005). More recently, we have shown that TNF- α also decreases ENaC expression and function in primary cultures of rat alveolar epithelial cells (Dagenais et al., 2004). Therefore, during the development of ALI/ARDS, overproduction of TNF- α in alveoli from various inflammatory cells may cause an impairment of alveolar liquid clearance due to an inhibition of ENaC.

However, it has been reported that TNF- α can also enhance alveolar liquid clearance, such as in a rat bacterial pneumonia model or intestinal ischemia-reperfusion model (Rezaiguia et al., 1997; Borjesson et al., 2000). Moreover, the instillation of TNF- α into a rat lung can also up-regulate the alveolar liquid clearance (Fukuda et al., 2001). More recently, Elia et al. (2003) have proposed a dual effect of TNF- α . That is to say, TNF- α can stimulate edema resorption through TNF receptor-independent effects, while TNF- α can also promote edema formation by means of TNF receptor-dependent effects. Therefore, there is still controversy concerning the role of TNF- α in the regulation of alveolar liquid clearance and active sodium transport.

The aim of the present study was to investigate whether TNF- α has an impact on ENaC expression during the development of ALI with pulmonary edema in an *in vivo* model, and that whether direct exposure of excess TNF- α , as seen in ALI, has an impact on ENaC regulation in freshly isolated alveolar type II epithelial cells (AT-II cells).

2. Methods

2.1. Materials

Phorbol myristate acetate (PMA) was purchased from SIGMA (St. Louis, USA). Minimum essential medium (MEM), Fetal bovine serum (FBS) and rat tumor necrosis factor- α (TNF- α) were purchased from Life Technologies (Tokyo, Japan). Anti-TNF- α antibody was purchased from SIGMA (Tokyo, Japan). Porcine pancreatic elastase was purchased from Worthington Biochemical (Lakewood, USA). PMA was dissolved in dimethyl sulfoxide (DMSO) and rat TNF- α was dissolved in the same media utilized for the cell culture. TRIzol reagent and SuperScriptTM II RNase H⁻ reverse transcriptase were also obtained from Life Technologies. Taq DNA polymerase was purchased from Promega (Madison, USA). Other materials and chemicals were purchased from Life Technologies and SIGMA.

2.2. *In vivo* study

2.2.1. Rat acute lung injury models

After male Sprague-Dawley rats (300–350g) were anesthetized by intraperitoneal injection of 50 mg/kg phenobarbital, an 18-gauge needle was inserted into the trachea. For the induction of lung injury, phorbol myristate acetate (PMA) solution (0.3 ml) was instilled into the rat trachea with a single instillation (a dose of PMA = 20, 40 μ g/300 g body weight). Control rats received an equivalent volume of saline. Untreated rats had only anesthesia by phenobarbital. During the study, the rats were maintained under anesthesia by Phenobarbital. The rats were sacrificed at 4 and 8 h after treatment with either PMA or saline, and then, pathological

and hematological findings, lung water volume and ENaC mRNA expression were evaluated. The protocols and procedure of the present study were approved by the animal care committee of our institution.

2.2.2. Pathological examination

After performing a surgical resection, whole rat lungs were fixed by instillation of 10% buffered formalin via the tracheal tube. After fixation, the specimens were processed and embedded with paraffin using routine techniques. The paraffin sections were stained with hematoxylin and eosin (HE) and then were examined using a light microscope.

2.2.3. Hematological examination

Blood samples were collected just after sacrifice. BAL was performed just before the sacrifice. Briefly, each 5 ml of saline was instilled and then collected 3 times. The number of total cells and white blood cells (WBC) in the blood and BAL samples and the number of macrophages in the BAL samples were counted using a Sysmex SE-9000 hematology analyzer (Sysmex, Kobe, Japan).

2.2.4. Measurement of TNF- α

Both blood and BAL samples were centrifuged at 4 °C, 3000 rpm for 5 min. Thereafter, the concentration of TNF- α in the supernatant was measured by an enzyme-linked immunosorbent assay system (Amersham Pharmacia Biotech, Piscataway, USA).

2.2.5. Measurement of lung water volume

To evaluate the lung water volume, the wet-to-dry lung weight ratio (W/D ratio) was measured as previously described (Selinger et al., 1975; Berthiaume et al., 1987). Briefly, the resected lung was homogenized and the weight of lung homogenate was measured. In each experiment, a 10 ml blood sample was also obtained and the blood weight was measured. In addition, the concentration of the hemoglobin in blood was measured. Thereafter, after the centrifugation of lung homogenate, the concentration of hemoglobin in the supernatant was also measured. Next, the W/D ratio was calculated by both the wet and dry lung weight (g water/g dry lung) adjusted for the lung hemoglobin concentration as described below. The weight of blood in the lung sample was calculated as follows:

$$Q_B = Q_H \times \left(\frac{Hb_{\text{supernatant}}}{Hb_{\text{blood}}} \right) \times \left(\frac{F_{WH}}{F_{WS}} \right) \times 1.06$$

where Q_B is the blood weight in the lung, Q_H is the weight of the lung homogenate, F_{WH} and F_{WS} are the fraction of water in the lung homogenate and in the supernatant obtained after centrifugation of the lung homogenate, respectively, and 1.06 is the density of blood in grams per milliliter. The weight of water in the lung sample was calculated as follows:

$$Q_{WL} = Q_H \times F_{WH} - Q_B \times F_{WB}$$

where Q_{WL} is the weight of water in the lung sample, F_{WB} is the fraction of water in blood. The weight of blood free dry lung weight was calculated as follows:

$${}_DQ_L = \text{weight of the lung sample} - Q_B - Q_{WL}$$

where ${}_DQ_L$ is the weight of blood free dry lung weight. Thereafter, W/D ratio was calculated as follows:

$$\frac{W}{D} \text{ ratio} = \frac{Q_{WL}}{{}_DQ_L}$$

2.2.6. Measurement of ENaC mRNA expression (RT-PCR)

As it has been reported that ENaC has three homologous subunits (α -, β - and γ -ENaC) (Canessa et al., 1994), a primer for each

Table 1
The primers for RT-PCR.

Gene	Primers	Product length (bp)
α -ENaC	5'-ACGCCTCCAACCTCGCCTAAG-3' 5'-GCCACAGCACGCCAGAAAG-3'	300
β -ENaC	5'-TGCCCAATGGGACCGTGTGA-3' 5'-GCCCCAGTGAAGATGTAGC-3'	244
γ -ENaC	5'-TGCAGTGGCCCTCATTATCT-3' 5'-TGGCCCTTCCCTTCTCATTTC-3'	326
β -Actin	5'-GAGGATATCGCTGCGCTGG-3' 5'-ATCTTTTCACGGTTGCGCT-3'	350

ENaC subunit was made. The primers used in the present study were purchased from TaKaRa Biomedicals (Shiga, Japan). The design of each primer was based on the published sequence (Table 1). The primer for α -ENaC amplified a fragment from nucleotides (nt) 50 to 350 of Genbank X70497; that for β -ENaC from nt 585 to 829 of Genbank X77932; that for γ -ENaC from nt 186 to 515 of Genbank X77933; and for β -actin from nt 7 to 356 of Genbank V01217.

The total cellular RNA was extracted from 1 g weight of lung tissue using Trizol reagent following the manufacturer's recommended protocol. The concentration of RNA was measured by absorbance at 260 nm. The reverse transcriptase (RT) reaction was performed using the SuperScript™ II following the manufacturer's instructions. Briefly, 1 μ g of total RNA was incubated in a 10 μ l reaction volume containing 100 μ g random primers at 70 °C for 10 min. Thereafter, the RT reaction was carried out with a 0.5 mM dNTP mixture, 10 mM dithiothreitol and 200 units SuperScript™ II in RT buffer (50 mM Tris-HCl, pH 8.3; 75 mM KCl and 3 mM MgCl₂) at 25 °C for 10 min, 42 °C for 50 min and 70 °C for 15 min.

The first strand cDNA was amplified in 10 mM Tris-HCl, pH 9.0, 50 mM KCl, 1.5 mM MgCl₂, 100 μ M dNTP mixture, 0.75 μ M specific primers and 0.75 units *Taq* DNA polymerase. The PCR reaction was performed in a GeneAmp PCR system 9700 (PE-Applied Biosystems, Foster City, USA) under the following conditions; 94 °C for 5 min (pre-PCR), 28 cycles of 94 °C for 30 s, 55 °C for 30 s, 72 °C for 30 s; and 72 °C for 7 min. The optimal cycle number (28 cycles) for each primer was determined by sequentially performed PCR amplification of 24, 26, 28, 30, 32 cycles. We confirmed that each DNA band of ENaC was linearly increased in these amplification cycles (Yamagata et al., 2002).

The PCR products were separated by electrophoresis loading onto a 3% agarose gel. After ethidium bromide staining, all DNA bands were photographed and a densitometric analysis was done using NIH imaging. Each DNA band was normalized by the amount of β -actin and then the expression of DNA was shown by the ratio to the value of a time-matched untreated rat.

2.3. In vitro study

2.3.1. Cell isolation and culture

Rat AT-II cells were freshly isolated from male Sprague-Dawley rats (200–250 g) as previously described (Dobbs, 1990; Yamagata et al., 2002). Briefly, the perfused rat lungs were digested with porcine pancreatic elastase solution. After the lungs were minced and filtered through 5 layers of gauze, 150 and 37 μ m nylon mesh, the cells were collected and then purified using a differential adhesion technique by panning onto rat IgG-coated plastic culture plates. Thereafter, AT-II cells were seeded into a 6-well plastic culture plate (9.5 cm²) at a density of 4 \times 10⁵ cells/cm² or a permeable filter membrane (Transwell, Coster Corning Incorporated, Corning, New York, USA) at a density of 1 \times 10⁶ cells/cm² and maintained at 37 °C in a humidified incubator containing 5% CO₂/95% air. After

reaching confluence, the AT-II cells in the plastic culture plate and Transwell were utilized to measure the mRNA expression of ENaC or the function of ENaC, respectively.

2.3.2. Measurement of ENaC mRNA expression (RT-PCR)

After 3 days culture, the AT-II cells were exposed to TNF- α at a concentration of 100 ng/ml. After 24 h exposure, total cellular RNA was extracted using Trizol reagent and then the mRNA expression of α -, β - and γ -ENaC was measured by RT-PCR as described above. Before performing this study, we confirmed whether this concentration of TNF- α had any effect on the cell viability of AT-II cells. After 24 h exposure with TNF- α , the viable cell number of AT-II cells in 6-well culture plate was 4.37 \pm 0.13 \times 10⁵ cells/cm², whereas 4.20 \pm 0.21 \times 10⁵ cells/cm² in control groups (no significant difference). In addition, there also was no significant difference in the levels of lactate dehydrogenase in supernatant between both groups (control = 35.0 \pm 5.9 IU/L, TNF- α 24 h = 30.8 \pm 9.3 IU/L).

The analysis of each DNA band was also performed in the same way as described above. The expression of each DNA is shown by the ratio to the value of time-matched non-treatment cells.

2.3.3. Measurement of amiloride-sensitive current

Potential differences (PD; mV) across the monolayers of AT-II cells and transepithelial resistance (R_{te} ; Ω /cm²) were measured with an epithelial tissue voltammeter (EVOMX; World Precision Instruments, Inc., Sarasota, USA) at 24 h after the initiation of treatment. After the culture of AT-II cells on the Transwell reached confluence, the cells were exposed to TNF- α (100 ng/ml) for 24 h. The transepithelial current (I_{te} ; μ A/cm²) across the monolayers of AT-II cells was calculated using the following formula: $I_{te} = PD/R_{te}$. To quantify the amount of amiloride-sensitive current, at the end of the measurements, amiloride was added at a final concentration of 1 μ M on the apical side. At this concentration, amiloride specifically inhibits a current dependent on ENaC. After 5 min incubation at 37 °C, PD and R_{te} were measured with EVOM again and then I_{te} was calculated. Amiloride-sensitive current (I_{ami}) was calculated by subtracting I_{te} after adding 1 μ M amiloride from I_{te} at 24 h.

2.4. Statistical analysis

All data are presented as the mean \pm SD. Comparisons among the groups were analyzed by unpaired *t*-test, a one factor analysis of variance (ANOVA) and post hoc comparison (Fisher's protected least significant difference). The level of significance was defined to be $p < 0.05$.

3. Results

3.1. In vivo, rat acute lung injury model

3.1.1. Pathological findings

After 4 h instillation of PMA at a concentration of 20 μ g/300 g body weight, infiltration of inflammatory cells such as neutrophils and macrophages to the alveolar septa was seen (Fig. 1C and D) in comparison to the control rat with saline instillation (Fig. 1A and B). In addition, the exudation of excess water into the alveolar lumen was also seen in some alveoli (Fig. 1F). However, these pathological changes were relatively mild, thus it was thought that these findings represented the mild early stage of acute lung injury and pulmonary edema.

When 40 μ g/300 g body weight PMA was instilled, similar pathological findings were seen (Fig. 1E). Therefore, we conducted the following experiments using PMA instillation at a dose of 20 μ g/300 g body weight.




Fig. 1. Pathological findings of the rat acute lung injury models by PMA instillation (hematoxylin and eosin staining. (A, C, E) $\times 100$, (B, D, F) $\times 200$). (A and B) Control rats instilled with 0.3 ml saline ($n=4$) showed no specific change as seen in the acute lung injury. In acute lung injury models, 0.3 ml PMA solution was instilled into rat trachea at a dose of 20 $\mu\text{g}/300\text{g}$ body weight (C, D, F, $n=4$) or 40 $\mu\text{g}/300\text{g}$ body weight (E, $n=4$). In comparison to the saline control rats, PMA instilled rat lung showed the infiltration of inflammatory cells including neutrophils and macrophages into the alveolar septa (C and D) and the accumulation of excess water into the alveolar lumen in some alveoli (F). These pathological changes were relatively mild and no apparent differences were seen between two PMA treated groups (C and E).

Table 2
Hematological findings of blood and BAL fluid.

	4h			8h		
	Untreated ($n=4$)	Saline ($n=4$)	PMA	Untreated ($n=4$)	Saline	PMA ($n=4$)
Blood ($\times 10^3/\text{ml}$)						
WBC	6.9 ± 0.6	7.3 ± 0.9	5.7 ± 1.9	7.7 ± 1.9	6.7 ± 1.2	6.3 ± 1.2
Neutrophils	1.7 ± 0.4	1.4 ± 0.4	$3.8 \pm 0.9^*$	1.6 ± 0.3	1.3 ± 0.3	$4.4 \pm 0.9^*$
Lymphocytes	5.1 ± 0.7	5.6 ± 1.1	$1.7 \pm 1.1^*$	5.9 ± 2.0	5.1 ± 1.4	$1.7 \pm 0.8^*$
BAL fluid ($\times 10^4/\text{ml}$)						
Total cell number	5.5 ± 0.6	4.5 ± 3.0	$10.6 \pm 2.1^*$	6.5 ± 1.3	5.3 ± 3.1	$18.8 \pm 3.6^*$
Neutrophils	1.0 ± 0.7	0.6 ± 0.4	$2.6 \pm 0.7^*$	1.6 ± 0.5	1.2 ± 1.0	$3.8 \pm 1.1^*$
Macrophages	4.4 ± 0.7	3.2 ± 2.5	$6.8 \pm 2.2^*$	4.7 ± 1.3	4.1 ± 2.1	$14.9 \pm 3.7^*$
Lymphocytes	0.2 ± 0.1	0.3 ± 0.3	1.1 ± 1.0	0.1 ± 0.1	0.1 ± 0.3	0.1 ± 0.5

* $p < 0.05$ vs. untreated and saline treated rats.

Please cite this article in press as: Yamagata, T., et al., The regulation of amiloride-sensitive epithelial sodium channels by tumor necrosis factor-alpha in injured lungs and alveolar type II cells. *Respir. Physiol. Neurobiol.* (2009), doi:10.1016/j.resp.2008.12.008

Table 3
Levels of TNF- α in serum and EAL fluid.

	4 h			8 h		
	Untreated (n=4)	Saline (n=4)	PMA	Untreated	Saline (n=4)	PMA
Serum	80.2 \pm 22.5	86.8 \pm 25.8	188.0 \pm 62.2*	71.1 \pm 38.0	80.3 \pm 41.3	164.8 \pm 81.1*
BAL fluid	76.6 \pm 32.5	79.3 \pm 15.9	181.1 \pm 35.8*	83.9 \pm 34.9	120.5 \pm 11.4	210.4 \pm 60.4*

* $p < 0.05$ vs. untreated and saline treated rats.

3.1.2. Hematological findings of blood and BAL fluid

After PMA instillation, a significant increase in the number of neutrophils in blood, but not WBC, was seen at 4 and 8 h in comparison to the saline instilled control rats (Table 2). In the BAL fluid, the number of total cells, neutrophils and macrophages increased significantly, but not lymphocytes (Table 2). There was no significant

difference in the cell numbers between the saline treated rats and untreated rats.

3.1.3. TNF- α concentration

The concentration of TNF- α in PMA treated rats was significantly higher in both the serum and BAL fluid than that in the saline treated




Fig. 2. Change of W/D ratio and regulation of ENaC mRNA expression in PMA instilled rat acute lung injury models. (A) Untreated rats ($n = 4$, hatched bars) had only anesthesia by intraperitoneal injection of phenobarbital. W/D ratio in untreated rats was 4.7 ± 0.1 at 4 h and 4.6 ± 0.1 at 8 h. W/D ratio in saline instilled control rats ($n = 4$, open bars) was 4.6 ± 0.1 at 4 h and 4.4 ± 0.2 at 8 h. There was no apparent difference between the untreated and control rats. In contrast, the PMA instilled rats ($20 \mu\text{g}/300 \text{g}$ body weight) showed a significant increase in the W/D ratio to 5.1 ± 0.1 at 4 h and 5.1 ± 0.2 at 8 h in comparison to the saline control rats ($n = 4$, solid bars; $p < 0.05$ vs. untreated rats and control rats). The expression of all three ENaC subunits was investigated in whole lung tissue after 4 and 8 h instillation of PMA ($20 \mu\text{g}/300 \text{g}$ body weight). Representative blots for α -, β -, γ -ENaC and β -actin expression at 4 and 8 h are shown under each graph, respectively. (B) The expression of α -ENaC mRNA was significantly inhibited to 80.2 ± 20.4 and $72.0 \pm 11.6\%$ in PMA treated rats ($n = 4$, solid bars) at 4 and 8 h in parallel with the development of pulmonary edema in comparison to those in the saline control rats ($n = 4$, open bars; $p < 0.05$ vs. control rats). Similarly, both β - (C) and γ -ENaC (D) expressions in PMA instilled rats ($n = 4$, solid bars) were also significantly inhibited to 47.8 ± 6.7 and $53.9 \pm 10.8\%$, respectively, but this inhibition was seen only at 8 h after instillation in comparison to the saline control rats ($n = 4$, open bars; $p < 0.05$ vs control rats).

Please cite this article in press as: Yamagata, T., et al., The regulation of amiloride-sensitive epithelial sodium channels by tumor necrosis factor-alpha in injured lungs and alveolar type II cells. *Respir. Physiol. Neurobiol.* (2009), doi:10.1016/j.resp.2008.12.008

Table 4
Change of transepithelial current (I_{te}).

	Control (n=12)	TNF- α (n=12)
I_{te} ($\mu\text{A}/\text{cm}^2$)		
Baseline	6.1 \pm 1.4	6.4 \pm 1.6
0.5 h	6.1 \pm 0.1	6.5 \pm 0.2
4 h	5.8 \pm 1.2	4.8 \pm 1.1*
6 h	5.7 \pm 1.5	4.7 \pm 1.3*
8 h	5.6 \pm 1.4	4.7 \pm 1.4*
24 h	7.9 \pm 1.2	5.5 \pm 0.3†

† $p < 0.01$.* $p < 0.05$ vs control.

control rats at 4 and 8 h. The untreated rats showed no difference in comparison to the saline treated rats (Table 3).

3.1.4. Lung water volume

The W/D ratio in the PMA treated rats was 5.1 ± 0.1 and 5.1 ± 0.2 at 4 and 8 h, respectively, which were significantly higher than those in the untreated rats (4.7 ± 0.1) and saline treated rats ($4 \text{ h } 4.6 \pm 0.1$, $8 \text{ h } 4.4 \pm 0.2$; Fig. 2A). No significant difference was seen between the untreated rats and saline treated rats.

3.1.5. mRNA expression of α -, β - and γ -ENaC in lung tissue

In acute lung injury rats, the mRNA expression of α -ENaC in the whole lung tissue was significantly inhibited at 4 and 8 h in comparison to the saline treated rats (Fig. 2B). Similarly, both β - and γ -ENaC mRNA expression was also inhibited. However, unlike α -ENaC, this inhibition was only seen at 8 h after PMA treatment (Fig. 2C and D). These data suggested that each ENaC mRNA expression was down-regulated during the development of lung injury and edema.

3.2. In vitro study

3.2.1. ENaC mRNA expression in AT-II cells

A representative RT-PCR band is shown in Fig. 3A. As shown in Fig. 3A, after 24 h exposure to 100 ng/ml TNF- α , the expression of α - and γ -ENaC was significantly inhibited to $64.0 \pm 11.8\%$ and $78.0 \pm 12.9\%$, respectively, in comparison to time-matched controls (both $p < 0.05$). On the contrary, there was no apparent difference in β -ENaC expression in comparison to time-matched controls ($92.5 \pm 15.4\%$).

3.2.2. Amiloride-sensitive current in AT-II cells

As shown in Table 4, TNF- α had no apparent impact on I_{te} for at least until 30 min. However, a significant decrease in I_{te} began after 4 h exposure to TNF- α and this inhibition was still seen after 24 h exposure. Although the I_{te} at 24 h showed some increase in both groups, TNF- α significantly inhibited I_{te} in comparison to the values of both the baseline and control ($p < 0.01$).

There was no apparent difference in the I_{ami} at baseline between the two groups (control $2.7 \pm 0.5 \mu\text{A}/\text{cm}^2$, TNF- α $2.6 \pm 0.7 \mu\text{A}/\text{cm}^2$). After the exposure to TNF- α , I_{ami} was significantly inhibited from baseline level to $2.0 \pm 0.6 \mu\text{A}/\text{cm}^2$ at 8 h and $1.9 \pm 0.8 \mu\text{A}/\text{cm}^2$ at 24 h, respectively. The I_{ami} in the TNF- α treated groups was also significantly inhibited in comparison to the time-matched control value (Fig. 3B).

The difference in the degree of I_{ami} between the TNF- α and control group was $0.6 \mu\text{A}/\text{cm}^2$ at 8 h and $2.5 \mu\text{A}/\text{cm}^2$ at 24 h. This difference was quite similar to the difference in the I_{te} between the control group and TNF- α treated group. ($0.9 \mu\text{A}/\text{cm}^2$ at 8 h, $2.4 \mu\text{A}/\text{cm}^2$ at 24 h $\mu\text{A}/\text{cm}^2$). In addition, when AT-II cells were pretreated with 20 $\mu\text{g}/\text{ml}$ anti-TNF- α antibody 30 min before TNF- α exposure, the decrease in I_{ami} at 24 h was inhibited (control $3.9 \mu\text{A}/\text{cm}^2$, TNF- α $3.5 \mu\text{A}/\text{cm}^2$, no significant difference). There-




Fig. 3. Impact of TNF- α on ENaC mRNA expression and amiloride-sensitive current (I_{ami}) in alveolar type II cells. (A) Representative blots for α -, β -, γ -ENaC and β -actin are shown under the graph. After 24 h exposure to TNF- α at a concentration of 100 ng/ml, mRNA expression of α - and γ -ENaC was significantly inhibited to $64.0 \pm 11.8\%$ and $78.0 \pm 12.9\%$, respectively ($n = 12$, solid bars; $p < 0.05$) in comparison to those of the control cells ($n = 6$, open bars), but not β -ENaC expression ($n = 12$, $92.5 \pm 15.4\%$). (B) At baseline, the I_{ami} was 2.7 ± 0.5 in the control cells ($n = 12$, open bars) and $2.6 \pm 0.7 \mu\text{A}/\text{cm}^2$ in the TNF- α treated cells ($n = 12$, solid bars). There was no apparent difference between them. At 8 h after the exposure to TNF- α at a concentration of 100 ng/ml, the I_{ami} was significantly inhibited to $2.0 \pm 0.6 \mu\text{A}/\text{cm}^2$ in comparison to the I_{ami} at baseline value ($p < 0.05$) and the I_{ami} in time-matched control cells ($2.6 \pm 1.0 \mu\text{A}/\text{cm}^2$, $p < 0.05$ vs time-matched control). At 24 h after the exposure to TNF- α , I_{ami} was persistently inhibited to $1.9 \pm 0.8 \mu\text{A}/\text{cm}^2$, which was significantly different from the I_{ami} at baseline value ($p < 0.05$) and the I_{ami} in time-matched control cells ($4.4 \pm 1.0 \mu\text{A}/\text{cm}^2$, $p < 0.01$ vs. time-matched control).

fore, it was assumed that the inhibition of transepithelial current by TNF- α was mainly due to the inhibition of the amiloride-sensitive current.

4. Discussion

The present study demonstrated a significant decrease in the ENaC mRNA expression in the whole lung tissue during the development of acute lung injury with pulmonary edema. During this process, a significant increase in neutrophils, which are considered to be the primary inflammatory cells contributing the development of lung injury, was detected in both the peripheral blood and BAL fluid. In addition, the level of TNF- α was also significantly higher in both the serum and BAL fluid when the lung injury occurred. In contrast with these pathophysiological changes, a significant inhibition of the expression of all three ENaC subunits was seen. As mentioned before, ENaC plays an important role in alveolar liquid clearance and maintaining the homeostasis in the lung. Therefore, the results of the present *in vivo* study suggest that the infiltration of inflammatory cells into the alveoli and the subsequent overproduction of TNF- α may inhibit the ENaC expression, which may cause, at least in part, the subsequent development of pulmonary edema.

TNF- α is one of the major pro-inflammatory cytokines and plays an important role in several inflammatory responses such as the activation of inflammatory cells, the release of several inflammatory cytokines and mediators and direct tissue or epithelial damage (Szatmary, 1999; Ware and Matthay, 2000). In addition, TNF- α is also known to increase vascular permeability (Stephens et al., 1988). Therefore, TNF- α , per se, would cause lung injury and pulmonary edema in the models used in the current study. However, in the present results, the elevation of TNF- α in the BAL fluid and the ENaC down regulation were seen coincidentally during pulmonary edema. This raises the possibility that alveolar epithelial cells might be directly and persistently exposed to an unphysiologically high concentration of TNF- α , thus causing an inhibition of the ENaC expression.

Because the inflammatory milieu in *in vivo* lung injury models is quite complicated and the effect of neutrophil depletion or inhibition of TNF- α by anti-TNF- α antibody have never been evaluated, there is a possibility that various inflammatory cells or cytokines besides TNF- α could be involved in the inhibition of ENaC expression. To clarify the direct impact of TNF- α on the regulation of ENaC, *in vitro* experiments were conducted using freshly isolated alveolar type II cells.

In the present *in vitro* study, a much higher concentration of TNF- α was selected. As shown in Table 3, the concentration of TNF- α in BAL fluid is around 0.2 ng/ml in the injured rat. However, considering the dilution by edema fluid or instilled saline in the BAL, the actual concentration of TNF- α is thought to be much higher in the alveoli. Therefore, in the *in vitro* study, to determine the impact of lethal dose of TNF- α on ENaC regulation, AT-II cells were treated with a very high concentration of TNF- α .

As shown in Fig. 3A, the direct exposure to 100 ng/ml TNF- α caused a significant inhibition in the expression of ENaC mRNA. In addition, as seen in Fig. 3B, TNF- α also significantly reduced the transepithelial current in the monolayers of AT-II cells. The transepithelial current in AT-II cells is generated by several ion channels and ion transporters located on apical and basolateral side. To assess the extent of the contribution of ENaC among these ion transporters, AT-II cells were treated with amiloride at a concentration of 1 μ M. This concentration of amiloride specifically inhibits the current dependent on ENaC function. According to the present results, the I_{ami} was significantly inhibited by TNF- α and the extent of this inhibition was quite similar to the reduction of the I_{te} . In addition, pretreatment with anti-TNF- α inhibited this reduction of I_{ami} by TNF- α exposure. These results suggest that the direct exposure to TNF- α can negatively regulate both ENaC expression and function. These results are consistent with the previous data by Northern blotting and short-circuit current (Dagenais et al., 2004). Taken together, it is thought that a high concentration of TNF- α affects a pathophysiology of pulmonary edema through regulation of alveolar liquid clearance followed by inhibition of ENaC in AT-II cells.

In the present study, to assess the function of ENaC, transepithelial current measured by EVOMX was used, rather than the short-circuit current by using a chamber. Although short-circuit current can show the acute impact of TNF- α on ENaC, it is not suitable for repeated measurements of current during chronic exposure. In contrast, the measurement of the transepithelial current by EVOMX can be easily repeated and performed for a longer time during chronic exposure. As shown in Table 4, it was possible to demonstrate that prolonged exposure with TNF- α caused the gradual and persistent inhibition of the transepithelial current and amiloride-sensitive current, which thus indicated the persistent inhibition of the ENaC function.

There have been several reports addressing the effect of TNF- α in alveolar liquid clearance and sodium transport. According to these reports, TNF- α can increase the alveolar liquid clearance in a rat bac-

teria pneumonia model or intestinal ischemia-reperfusion model. Namely, Rezaiguia et al. (1997) demonstrated that the increase in alveolar liquid clearance is inhibited by amiloride and anti TNF- α antibody and that the instillation of TNF- α into a normal rat trachea increases alveolar liquid clearance. Borjesson et al. (2000) also showed that the alveolar liquid clearance increases to 76% during intestinal ischemia-reperfusion and this increase is also inhibited by amiloride and anti TNF- α antibody. In addition, Fukuda et al. reported that TNF- α increases the amiloride-inhibitable sodium current as shown by patch clamp recordings (Fukuda et al., 2001). A discrepancy between these results and our present results was observed in regard to the fact that TNF- α inhibits ENaC expression and function. One possible explanation of this discrepancy is due to the acute or chronic exposure with TNF- α in each experimental model. However, the different exposure time cannot clearly explain the impact of TNF- α .

Another more plausible explanation of the discrepancy is the dichotomous effect of TNF- α in alveolar liquid clearance by different signaling pathways. It has been previously reported that TNF- α mediates the alveolar liquid clearance by a TNF- α receptor independent signaling system (Elia et al., 2003). According to that report, TNF- α could promote alveolar liquid clearance in TNF receptor deficient mice and some proper structure of TNF- α mimicking a lectin-like domain plays a role in this effect. In contrast, it has more recently been demonstrated that TNF- α can decrease alveolar liquid clearance via the TNF receptor, while TNF- α can inversely increase alveolar liquid clearance when receptor binding site of TNF- α is blocked by soluble TNF receptor type I construct (Braun et al., 2005). These results suggest that TNF- α can both increase and decrease alveolar liquid clearance. Although the exact mechanism of TNF- α induced inhibition of ENaC is still under investigation, it is likely that TNF receptor dependent signaling mechanism may play a role in the inhibitory regulation of ENaC and subsequent reduction of alveolar liquid clearance.

In conclusion, the mRNA expression of ENaC in the lung was significantly inhibited in parallel with the development of pulmonary edema and the increase in the level of TNF- α in the BAL fluid. In addition, the direct exposure with TNF- α significantly inhibited both the mRNA expression and the function of ENaC. Although, further investigation is necessary to clarify the exact regulatory mechanism of ENaC by TNF- α , TNF- α is considered to possibly play a role in the pathophysiology of acute lung injury and pulmonary edema through the regulation of alveolar liquid clearance and sodium transport, and the blocking of this TNF- α effect may become a potentially effective therapeutic strategy for treating pulmonary edema.

References

- Bernard, G.R., Artigas, A., Brigham, K.L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J.R., Morris, A., Spragg, R., 1994. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. The American-European Consensus Conference on ARDS. *Am. J. Respir. Crit. Care Med.* 149, 818–824.
- Berthiaume, Y., Staub, N.C., Matthay, M.A., 1987. Beta-adrenergic agonists increase lung liquid clearance in anesthetized sheep. *J. Clin. Invest.* 79, 335–343.
- Berthiaume, Y., 1998. Mechanisms of edema clearance. In: Weir, E.K., Reeves, J.T. (Eds.), *Pulmonary Edema*. Futura Publishing Company, Armonk, pp. 77–94.
- Borjesson, A., Norlin, A., Wang, X., Andersson, R., Folkesson, H.G., 2000. TNF- α stimulates alveolar liquid clearance during intestinal ischemia-reperfusion in rats. *Am. J. Physiol. Lung Cell Mol. Physiol.* 278, L3–L12.
- Braun, C., Hamacher, J., Morel, D.R., Wendel, A., Lucas, R., 2005. Dichotomous role of TNF in experimental pulmonary edema reabsorption. *J. Immunol.* 175, 3402–3408.
- Canessa, C.M., Schild, L., Buell, G., Thorens, B., Gautschi, I., Horisberger, J.D., Rossier, B.C., 1994. Amiloride-sensitive epithelial Na⁺ channel is made of three homologous subunits. *Nature* 367, 463–467.
- Champigny, G., Voilley, N., Liguoglia, E., Friend, V., Barbry, P., Lazdunski, M., 1994. Regulation of expression of the lung amiloride-sensitive Na⁺ channel by steroid hormones. *EMBO J.* 13, 2177–2181.
- Dagenais, A., Denis, C., Vives, M.F., Girouard, S., Masse, C., Nguyen, T., Yamagata, T., Grygorczyk, C., Kothary, R., Berthiaume, Y., 2001. Modulation of alpha-ENaC and

- alpha1-Na⁺-K⁺-ATPase by cAMP and dexamethasone in alveolar epithelial cells. *Am. J. Physiol. Lung Cell Mol. Physiol.* 281, L217-230.
- Dagenais, A., Frechette, R., Yamagata, Y., Yamagata, T., Carmel, J.F., Clermont, M.E., Brochiero, E., Masse, C., Berthiaume, Y., 2004. Downregulation of ENaC activity and expression by TNF-alpha in alveolar epithelial cells. *Am. J. Physiol. Lung Cell Mol. Physiol.* 286, L301-311.
- Dobbs, L.G., 1990. Isolation and culture of alveolar type II cells. *Am. J. Physiol.* 258, L134-147.
- Elia, N., Taponnier, M., Matthay, M.A., Hamacher, J., Pache, J.C., Brundler, M.A., Totsch, M., De Baetselier, P., Fransen, L., Fukuda, N., Morel, D.R., Lucas, R., 2003. Functional identification of the alveolar edema reabsorption activity of murine tumor necrosis factor-alpha. *Am. J. Respir. Crit. Care Med.* 168, 1043-1050.
- Fukuda, N., Jayr, C., Lazrak, A., Wang, Y., Lucas, R., Matalon, S., Matthay, M.A., 2001. Mechanisms of TNF-alpha stimulation of amiloride-sensitive sodium transport across alveolar epithelium. *Am. J. Physiol. Lung Cell Mol. Physiol.* 280, L1258-1265.
- Hummeler, E., Barker, P., Gatzky, J., Beermann, F., Verdumo, C., Schmidt, A., Boucher, R., Rossier, B.C., 1996. Early death due to defective neonatal lung liquid clearance in alpha-ENaC-deficient mice. *Nat. Genet.* 12, 325-328.
- Matalon, S., O'Brodovich, H., 1999. Sodium channels in alveolar epithelial cells: molecular characterization, biophysical properties, and physiological significance. *Annu. Rev. Physiol.* 61, 627-661.
- Matthay, M.A., Wiener-Kronish, J.P., 1990. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. *Am. Rev. Respir. Dis.* 142, 1250-1257.
- Matthay, M.A., Folkesson, H.G., Verkman, A.S., 1996. Salt and water transport across alveolar and distal airway epithelia in the adult lung. *Am. J. Physiol.* 270, L487-503.
- Minakata, Y., Suzuki, S., Grygorczyk, C., Dagenais, A., Berthiaume, Y., 1998. Impact of beta-adrenergic agonist on Na⁺ channel and Na⁺-K⁺-ATPase expression in alveolar type II cells. *Am. J. Physiol.* 275, L414-422.
- O'Brodovich, H.M., 1995. The role of active Na⁺ transport by lung epithelium in the clearance of airspace fluid. *New Horiz.* 3, 240-247.
- Rezaiguia, S., Garat, C., Delclaux, C., Meignan, M., Fleury, J., Legrand, P., Matthay, M.A., Jayr, C., 1997. Acute bacterial pneumonia in rats increases alveolar fluid clearance by a tumor necrosis factor-alpha-dependent mechanism. *J. Clin. Invest.* 99, 325-335.
- Rossier, B.C., Canessa, C.M., Schild, L., Horisberger, J.D., 1994. Epithelial sodium channels. *Curr. Opin. Nephrol. Hypertens.* 3, 487-496.
- Selinger, S.L., Bland, R.D., Demling, R.H., Staub, N.C., 1975. Distribution volumes of [¹³¹I]albumin, [¹⁴C]sucrose, and ³⁶Cl in sheep lung. *J. Appl. Physiol.* 39, 773-779.
- Stephens, K.E., Ishizaka, A., Larrick, J.W., Raffin, T.A., 1988. Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. *Am. Rev. Respir. Dis.* 137, 1364-1370.
- Suter, P.M., Suter, S., Girardin, E., Roux-Lombard, P., Grau, G.E., Dayer, J.M., 1992. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. *Am. Rev. Respir. Dis.* 145, 1016-1022.
- Szatmary, Z., 1999. Tumor necrosis factor-alpha: molecular-biological aspects. *Mini review. Neoplasma* 46, 257-266.
- Tchepichev, S., Ueda, J., Canessa, C., Rossier, B.C., O'Brodovich, H., 1995. Lung epithelial Na channel subunits are differentially regulated during development and by steroids. *Am. J. Physiol.* 269, C805-C812.
- Tracey, K.J., Cerami, A., 1993. Tumor necrosis factor: an updated review of its biology. *Crit. Care Med.* 21, S415-422.
- Ware, L.B., Matthay, M.A., 2000. The acute respiratory distress syndrome. *N. Engl. J. Med.* 342, 1334-1349.
- Ware, L.B., Matthay, M.A., 2001. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. *Am. J. Respir. Crit. Care Med.* 163, 1376-1383.
- Yamagata, T., Yamagata, Y., Nishimoto, T., Nakanishi, M., Nakanishi, H., Minakata, Y., Mune, M., Yukawa, S., 2002. The impact of phorbol ester on the regulation of amiloride-sensitive epithelial sodium channel in alveolar type II epithelial cells. *Exp. Lung Res.* 28, 543-562.
- Yamagata, T., Yamagata, Y., Masse, C., Tessier, M.C., Brochiero, E., Dagenais, A., Berthiaume, Y., 2005. Modulation of Na⁺ transport and epithelial sodium channel expression by protein kinase C in rat alveolar epithelial cells. *Can. J. Physiol. Pharmacol.* 83, 977-987.

Awarded Article, Annual Meeting of JSA

Molecular Mechanism of the Additive Effects of Leukotriene Modifier in Asthmatic Patients Receiving Steroid Therapy

Kazuto Matsunaga¹, Satoru Yanagisawa¹, Tomohiro Ichikawa¹, Keiichiro Akamatsu¹, Akira Koarai¹, Tsunahiko Hirano¹, Hisatoshi Sugiura¹, Yoshiaki Minakata¹ and Masakazu Ichinose¹

ABSTRACT

Background: The addition of leukotriene modifier (LM) may be a useful approach for uncontrollable asthma despite treatment with inhaled corticosteroid (ICS), especially in asthmatics comorbid with allergic rhinitis (AR), although little is known about its molecular mechanism. We evaluated the additive effects of LM with ICS on pulmonary function and airway inflammation in asthmatics with or without AR.

Methods: Eighteen uncontrolled steroid-treated asthmatics, nine with and nine without AR, were enrolled. Spirometry, peak expiratory flow (PEF) measurements, and exhaled breath condensate sampling were performed before and 8 weeks after LM administration. The lowest PEF over the course of one week, expressed as a percentage of the highest PEF (Min%Max PEF), was used as an index of fluctuation of the airway caliber. Airway cytokine expression was analyzed with a protein array.

Results: A significant improvement in forced expiratory volume in one second as a percentage of the predicted value (%FEV₁) and Min%Max PEF was seen in the subgroup of asthma with AR. Although there was no significant difference in the baseline cytokine values between the groups, the exhaled RANTES level was significantly reduced by LM in the asthma with AR group. The changes in the RANTES level were significantly related to the changes in the %FEV₁ and Min%Max PEF values.

Conclusions: LM caused a greater improvement in pulmonary function and airway inflammation in asthmatics with AR. The RANTES-mediated pathway may be involved in the improvement of the airflow limitation and airway lability by LM additive therapy in asthmatics receiving steroid therapy.

KEY WORDS

airflow limitation, airway hyperresponsiveness, airway lability, exhaled breath condensate, RANTES

INTRODUCTION

A basic pathological feature of asthma and allergic rhinitis (AR) is airway inflammation, in which various inflammatory cells and molecules produced from them are involved.¹ The cysteinyl leukotrienes (CysLTs), common mediators of asthma and AR, induce bronchoconstriction and mucus hypersecretion, enhance airway responsiveness, and act as chemoattractants for eosinophils in the airway.² Leukotriene

modifier (LM) has proven to be effective in the treatment of both asthma and AR, and is the only drug approved to treat both diseases in a single formulation.³⁻⁵

Despite treatment with inhaled corticosteroids (ICS), the suppression of inflammation in asthmatic airways is often incomplete,⁶ and their effect on CysLTs biosynthesis is limited.^{7,8} It has been demonstrated that LM added to ICS was as efficacious as double the dose of ICS in improving peak expiratory

¹Third Department of Internal Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan.
Correspondence: Masakazu Ichinose, MD, PhD, Third Department of Internal Medicine, Wakayama Medical University, School of

Medicine, 811-1 Kimiidera, Wakayama 641-0012, Japan.
Email: masakazu@wakayama-med.ac.jp
Received 10 June 2008. Accepted for publication 20 July 2008.
©2009 Japanese Society of Allergology